Literature DB >> 23696020

High SKIP expression is correlated with poor prognosis and cell proliferation of hepatocellular carcinoma.

Guoliang Liu1, Xiaodong Huang, Xiaopeng Cui, Jing Zhang, Lixian Wei, Runzhou Ni, Cuihua Lu.   

Abstract

Ski-interacting protein (SKIP) is a transcriptional cofactor distinct from other cofactors and involved in the regulation of many cancer-related proteins. This study investigated the expression of SKIP and its potential clinical and biological significances in hepatocellular carcinoma (HCC). Immunohistochemistry and Western blot were performed to detect the expression of SKIP in clinical HCC samples and adjacent noncancerous tissues. In addition, expression of SKIP was correlated with clinicopathological variables, and univariate and multivariate survival analyses were performed to determine the prognostic significance. Moreover, the biological significance of the aberrant expression of SKIP was investigated in vitro. High SKIP expression was detected in clinical HCC samples compared with adjacent noncancerous tissues. Expression of SKIP correlated directly with the histological grades of HCC and high expression of SKIP was associated with a poor prognosis. SKIP depletion by small interfering RNA inhibited cell proliferation and blocked S phase entry in HepG2 cells. Owing to overexpression of SKIP in HCC tissues and its important role in predicting poor prognosis and the development of HCC, SKIP could be a potential prognostic marker and therapeutic target of HCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23696020     DOI: 10.1007/s12032-013-0537-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

Review 1.  The E2F transcription factors: key regulators of cell proliferation.

Authors:  H Müller; K Helin
Journal:  Biochim Biophys Acta       Date:  2000-02-14

2.  E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation.

Authors:  Qing Deng; Qun Wang; Wei-Ying Zong; Da-Li Zheng; Yi-Xin Wen; Ke-Sheng Wang; Xiao-Mei Teng; Xin Zhang; Jian Huang; Ze-Guang Han
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

Review 3.  Hepatocellular carcinoma: A global view.

Authors:  Ju Dong Yang; Lewis R Roberts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07-13       Impact factor: 46.802

4.  Solution structure of human peptidyl prolyl isomerase-like protein 1 and insights into its interaction with SKIP.

Authors:  Chao Xu; Jiahai Zhang; Xiaojuan Huang; Jianping Sun; Yingqi Xu; Yajun Tang; Jihui Wu; Yunyu Shi; Qiuhua Huang; Qinghua Zhang
Journal:  J Biol Chem       Date:  2006-04-04       Impact factor: 5.157

5.  SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: clinical implication and functional analysis in vitro.

Authors:  Wonhee Hur; Hyangshuk Rhim; Chan Kwon Jung; Jin Dong Kim; Si Hyun Bae; Jeong Won Jang; Jin Mo Yang; Seong-Taek Oh; Dong Goo Kim; Hee Jung Wang; Sean Bong Lee; Seung Kew Yoon
Journal:  Carcinogenesis       Date:  2010-04-16       Impact factor: 4.944

6.  SKLB70326, a novel small-molecule inhibitor of cell-cycle progression, induces G₀/G₁ phase arrest and apoptosis in human hepatic carcinoma cells.

Authors:  Yuanyuan Han; Haiyun He; Feng Peng; Jiyan Liu; Xiaoyun Dai; Hongjun Lin; Youzhi Xu; Tian Zhou; Yongqiu Mao; Gang Xie; Shengyong Yang; Luoting Yu; Li Yang; Yinglan Zhao
Journal:  Biochem Biophys Res Commun       Date:  2012-04-21       Impact factor: 3.575

7.  Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer.

Authors:  Shuli Liu; Qianze Dong; Enhua Wang
Journal:  Tumour Biol       Date:  2012-04-20

8.  Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas.

Authors:  Xundi Xu; Hirofumi Yamamoto; Masato Sakon; Masayoshi Yasui; Chew Yee Ngan; Hiroki Fukunaga; Tetsushi Morita; Minoru Ogawa; Hiroaki Nagano; Shoji Nakamori; Mitsugu Sekimoto; Nariaki Matsuura; Morito Monden
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

Review 9.  Transcriptional coregulator SNW/SKIP: the concealed tie of dissimilar pathways.

Authors:  P Folk; F Půta; M Skruzný
Journal:  Cell Mol Life Sci       Date:  2004-03       Impact factor: 9.261

10.  Expression and prognostic role of Spy1 as a novel cell cycle protein in hepatocellular carcinoma.

Authors:  Qing Ke; Juling Ji; Chun Cheng; Yixin Zhang; Mudan Lu; You Wang; Li Zhang; Peng Li; Xiaopeng Cui; Li Chen; Song He; Aiguo Shen
Journal:  Exp Mol Pathol       Date:  2009-08-15       Impact factor: 3.362

View more
  5 in total

Review 1.  Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis.

Authors:  Yihuan Luo; Fanghui Ren; Yongru Liu; Zhenhong Shi; Zhong Tan; Huojie Xiong; Yiwu Dang; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  SKIP expression is correlated with clinical prognosis in patients with bladder cancer.

Authors:  Longwang Wang; Mei Zhang; Yong Wu; Cheng Cheng; Yawei Huang; Zimin Shi; Hongwei Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

3.  Upregulated expression of ubiquitin-conjugating enzyme E2Q1 (UBE2Q1) is associated with enhanced cell proliferation and poor prognosis in human hapatocellular carcinoma.

Authors:  Renan Chang; Lixian Wei; Yuhua Lu; Xiaopeng Cui; Cuihua Lu; Luoliang Liu; Dawei Jiang; YiCheng Xiong; Gang Wang; Chunhua Wan; Haixin Qian
Journal:  J Mol Histol       Date:  2014-10-14       Impact factor: 2.611

4.  Thioredoxin reductase: a novel, independent prognostic marker in patients with hepatocellular carcinoma.

Authors:  Chunyan Li; Yan Peng; Binglang Mao; Kun Qian
Journal:  Oncotarget       Date:  2015-07-10

5.  Identification and validation of key biomarkers for the early diagnosis of diabetic kidney disease.

Authors:  Wei Yu; Ting Wang; Feng Wu; Yiding Zhang; Jin Shang; Zhanzheng Zhao
Journal:  Front Pharmacol       Date:  2022-08-22       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.